Doximity (DOCS) Q3 2026: AI Tools Reach 300,000 Physicians, Unlocking New Commercial Pathways
Doximity’s third quarter saw record physician engagement and rapid AI adoption, but near-term revenue growth was dampened by pharma policy headwinds and delayed client budgets. AI infrastructure investment is rising as usage surges, setting up a pivotal year for monetization. Management eyes a double-digit exit growth rate as pharma spend normalizes and new AI products reach market.
Summary
- AI Adoption Accelerates: Over 300,000 prescribers used Doximity’s AI tools, driving record workflow engagement.
- Pharma Budget Timing Disrupts Growth: Delayed top 20 pharma spend and policy uncertainty slowed Q4 outlook.
- Monetization Inflection Ahead: Commercial AI offerings and search budgets set to unlock new revenue streams later in 2026.
Business Overview
Doximity operates a digital platform for U.S. healthcare professionals, monetizing via subscription-based marketing and workflow tools for pharmaceutical, hospital, and health system clients. Its core segments include digital marketing solutions for pharma, workflow and telehealth tools (Doximity Dialer, digital fax, scheduling), and a growing AI clinical suite (DocsGPT, Scribe). The company’s platform reaches more than 85% of U.S. physicians and two-thirds of nurse practitioners (NPs) and physician assistants (PAs).
Performance Analysis
Doximity delivered 10% year-over-year revenue growth in Q3, outperforming guidance and maintaining robust 60% adjusted EBITDA margins. The company’s largest customers continue to drive results, with the top 20 clients showing 117% net revenue retention and accounting for 84% of total revenue. The number of customers contributing at least $500,000 in annual subscription revenue rose 10% to 126, underscoring concentration among sophisticated pharma buyers.
However, Q4 guidance reflects a marked deceleration, as widespread policy uncertainty and late-signed “most favored nation” (MFN) agreements with the White House led top pharma clients to delay budget deployment and push deals into the new year. This anomaly in the annual buying cycle resulted in a lower upfront spend, with management expecting a catch-up in the mid-year upsell season as budgets are released. Meanwhile, AI infrastructure costs rose due to surging usage, compressing gross margin by 200 basis points year-over-year.
- Workflow Engagement Jumps: Unique active prescribers hit 720,000, the largest sequential gain, driven by telehealth and new AI tools.
- AI Usage Surges: 300,000+ prescribers used DocsGPT, and 100 top health systems purchased AI suite access for 180,000 clinicians.
- Bookings Timing Skewed: January saw the highest pharma bookings growth rate since IPO, reflecting delayed Q3 decisions.
Cash flow remains robust, with $58.5 million in free cash flow and $735 million in cash and equivalents. Share repurchases accelerated, with $196.8 million bought back in Q3 and a new $500 million buyback authorization approved.
Executive Commentary
"In our first full quarter since acquiring Pathway AI in August, we've already become one of the most used AI tools by physicians... Over 300,000 unique prescribers used our AI products in Q3."
Jeff Tangney, Co-founder and CEO
"Despite our Q3 outperformance, the midpoint of our annual outlook remains in line with our prior guidance. This is the result of lower Q4 revenue expectations and higher AI infrastructure investment, driven by a strong increase in usage."
Tim Cabral, Audit Committee Chair and Interim CFO
Strategic Positioning
1. AI Platform as a Differentiator
Doximity’s rapid AI adoption positions it as the leading trusted digital platform for physicians. The DocsGPT suite is uniquely integrated with deterministic drug references and exclusive journal access, allowing the company to win head-to-head physician preference trials. The “PeerCheck” program, leveraging a network of 10,000 expert reviewers, delivers trust and compliance advantages as hospitals and clinicians demand validated, safe AI tools.
2. Pharma Budget Dynamics and Policy Risk
Late-breaking MFN agreements and policy uncertainty delayed budget releases from top pharma clients, compressing near-term revenue growth. However, management expects unreleased funds to return during the mid-year upsell season, with clients seeking high-ROI digital channels as regulatory scrutiny increases on direct-to-consumer (DTC) marketing.
3. Commercialization of AI and Search
No AI revenue is currently in guidance, but Doximity plans to launch commercial AI products later in 2026, unlocking new innovation and search budgets. Paid search, which represents 55% of healthcare digital marketing spend, is a significant new addressable market for the company.
4. Workflow Ecosystem and Health System Penetration
Doximity’s workflow tools (telehealth, scheduling, digital fax, Scribe) now reach 20% of U.S. doctors via health system contracts, with a clear path to expand further. Integration with EHRs remains light but effective, with platform stickiness driven by ease of use, high call pickup rates, and trusted relationships with hospital CIOs.
5. Capital Allocation and Margin Discipline
Share repurchases and disciplined investment in AI infrastructure signal confidence in long-term cash flows. Management reiterated a 50% adjusted EBITDA margin floor, leveraging industry-leading profitability to fund innovation while maintaining financial flexibility.
Key Considerations
Doximity’s Q3 reveals a business at an inflection point: AI-driven engagement is surging, but near-term growth is clouded by pharma budget delays and regulatory noise. The company’s ability to convert usage into revenue and sustain its high-margin model will be tested as commercial AI products roll out and the competitive landscape evolves.
Key Considerations:
- AI Trust Moat: PeerCheck’s 10,000 expert reviewers and deep journal integration set Doximity apart from generic AI competitors.
- Pharma Spend Recovery Watch: Mid-year upsell season is critical for recapturing delayed budgets and returning to double-digit growth rates.
- Commercialization Execution: Timely launch and adoption of AI and search offerings will determine the pace of new revenue streams.
- Margin Management: Sustaining 50%+ EBITDA margins while funding AI infrastructure and talent in a competitive market remains a balancing act.
- Platform Stickiness: Workflow tool integration and health system contracts continue to drive engagement and defend against point-solution entrants.
Risks
Delayed pharma budgets and policy-driven uncertainty could persist or recur, impacting revenue visibility and growth pacing. AI infrastructure costs may remain elevated as usage grows ahead of monetization, compressing margins. Competitive threats from established digital health and AI players, as well as evolving regulatory scrutiny on both pharma marketing and medical AI, represent ongoing risks to Doximity’s differentiated positioning and profitability.
Forward Outlook
For Q4 2026, Doximity guided to:
- Revenue of $143–$144 million (4% YoY growth midpoint)
- Adjusted EBITDA of $63.5–$64.5 million (45% margin)
For full-year 2026, management maintained guidance:
- Revenue of $642.5–$643.5 million (13% YoY growth midpoint)
- Adjusted EBITDA of $355.5–$356.5 million (55% margin)
Management highlighted:
- Upsell Season Opportunity: Unreleased pharma budgets likely to be deployed later in the year, supporting a double-digit exit growth rate.
- AI Monetization: Commercial AI products expected in market later in 2026, with no current revenue contribution in guidance.
Takeaways
- AI-Driven Engagement: Doximity’s platform now anchors physician workflow and clinical decision-making, with AI adoption outpacing competitors and setting up new monetization vectors.
- Short-Term Revenue Drag: Pharma policy delays and budget uncertainty are transitory but significant, with Q4 growth muted and recovery hinging on mid-year budget releases.
- Watch for Commercial AI Launch: The pace and scale of AI and search product monetization will be the defining catalyst for Doximity’s growth narrative in the second half of 2026 and beyond.
Conclusion
Doximity’s Q3 2026 underscores its strategic shift from digital marketing platform to AI-powered clinical workflow hub. While near-term growth is hampered by external pharma budget dynamics, surging physician engagement and a clear roadmap to commercial AI offerings position the company for renewed double-digit growth and margin resilience as the year progresses.
Industry Read-Through
Doximity’s experience highlights a broader digital health trend: AI tools are rapidly moving from pilot to platform scale, but monetization lags usage as buyers and regulators demand trust, transparency, and integration with clinical workflows. Pharma’s digital marketing budgets remain sensitive to policy shocks, with delayed decision cycles impacting all vendors reliant on annual upfront spend. The shift toward paid search and innovation budgets signals new revenue pools for platforms that can combine high engagement with trusted clinical AI, while point solutions and generic AI tools face increasing barriers to adoption in regulated healthcare environments.